文献速递脑血管病外科

ARUBA试验合格未破裂脑动静脉畸形患者的随机试验治疗结局

Treatment Outcomes of A Randomized Trial of Unruptured Brain Arteriovenous Malformation-Eligible Unruptured Brain Arteriovenous Malformation Patients.
PubMed 文献 · Neurosurgery · 2018-01-01

本机构2001至2014年回顾性分析673例脑动静脉畸形患者,其中105例符合ARUBA标准,按最终治疗分为显微手术组或伽玛刀放射外科(GKS)组。卒中或死亡总体风险为显微手术组11.4%(5/44)vs GKS组4.9%(3/61);作者认为本机构ARUBA合格患者治疗后卒中或死亡风险低于ARUBA,显微手术和GKS可能是未破裂脑动静脉畸形的合适治疗。

要点

  • 显微手术组卒中或死亡风险11.4%(5/44),GKS组4.9%(3/61)。
  • 随访结束时畸形血管团闭塞率显微手术组95.5%,GKS组47.5%。
  • 作者认为显微手术和GKS可能是未破裂脑动静脉畸形的合适治疗。

核心结论

  • 本机构ARUBA合格患者治疗后卒中或死亡总体风险低于ARUBA报告的风险。
  • 作者认为显微手术和GKS可能是未破裂脑动静脉畸形患者的合适治疗。

研究设计与样本

  • 回顾性分析本机构2001年至2014年治疗的673例脑动静脉畸形患者。
  • 其中105例符合ARUBA标准并纳入研究,按最终治疗分为显微手术组或伽玛刀放射外科(GKS;Elekta,斯德哥尔摩,瑞典)组。
  • 平均随访43个月(范围4至136个月)。
  • 主要结局为卒中或死亡。

主要发现

  • 共8例(7.6%)患者发生卒中或死亡。
  • 卒中或死亡总体风险:显微手术组11.4%(5/44)vs GKS组4.9%(3/61)。
  • 卒中或死亡年发生率:整个队列2.1%,显微手术组4.0%,GKS组1.2%。
  • 随访结束时畸形血管团闭塞率:显微手术组95.5% vs GKS组47.5%。

临床怎么用

  • 作者认为显微手术和GKS可能是未破裂脑动静脉畸形患者的合适治疗。

局限性

  • ARUBA研究存在诸多局限性,包括随访期短以及接受手术和栓塞治疗的患者数量不成比例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The guideline for treating unruptured brain arteriovenous malformations (ubAVMs) remains controversial. A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) reported lower risk of stroke or death with conservative management compared to interventional treatment. There were numerous limitations to the study, including short follow-up period and disproportionate number of patients treated with surgery and embolization. OBJECTIVE: To evaluate whether treatment of ARUBA-eligible patients have acceptable outcomes at our institution. METHODS: Retrospective analysis was performed on 673 patients with brain AVMs treated at our institution between 2001 and 2014. One hundred five patients were ARUBA eligible and included in the study. Patients were divided into the microsurgery or Gamma Knife Radiosurgery (GKS; Elekta, Stockholm, Sweden) arm depending on their final treatment. Mean follow-up period was 43 mo (range 4-136 mo). Primary outcome was stroke or death. RESULTS: A total of 8 (7.6%) patients had a stroke or died. The overall risk of stroke or death was 11.4% (5 of 44 patients) for the microsurgery arm and 4.9% (3 of 61 patients) for the GKS arm. The annual rates of stroke or death were 2.1%, 4.0%, and 1.2% for the entire patient cohort, microsurgery arm, and GKS arm, respectively. AVM obliteration rates at the end of the follow-up period were 95.5% and 47.5% for the microsurgery and GKS arms, respectively. CONCLUSION: We report a lower overall risk of stroke or death in our ARUBA-eligible patients following treatment than ARUBA. Our results suggest that microsurgery and GKS may be appropriate treatments for patients with ubAVM.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Lang M, Moore NZ, Rasmussen PA, et al. Treatment Outcomes of A Randomized Trial of Unruptured Brain Arteriovenous Malformation-Eligible Unruptured Brain Arteriovenous Malformation Patients. Neurosurgery. 2018. PMID: 29040773. doi:10.1093/neuros/nyx506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。